A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
- Interventions
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03730012
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03698305
- Locations
- 🇺🇸
Covance CRU, Daytona Beach, Daytona Beach, Florida, United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort
- First Posted Date
- 2018-09-24
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT03682484
- Locations
- 🇺🇸
Parexel - Baltimore, Baltimore, Maryland, United States
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or CancerMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 507
- Registration Number
- NCT03653507
- Locations
- 🇺🇸
Pacific Cancer Care, Monterey, California, United States
🇺🇸University of Kansas Cancer Center and Medical Pavilion, Fairway, Kansas, United States
🇺🇸Ochsner Clinic CCOP, New Orleans, Louisiana, United States
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT03565445
- Locations
- 🇺🇸
Yale Center for Clinical Investigation, New Haven, Connecticut, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Cancer Center at Greater Baltimore Medical, Baltimore, Maryland, United States
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 233
- Registration Number
- NCT03557931
- Locations
- 🇺🇸
CNS Research Science, Inc., Jamaica, New York, United States
🇺🇸Collaborative Neuroscience Network, LLC, Torrance, California, United States
🇺🇸Synergy East, Lemon Grove, California, United States
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
- Conditions
- Pharmacokinetics of ZolbetuximabGastric CancerPharmacokinetics of OxaliplatinGastro-esophageal Junction (GEJ) CancerPharmacokinetics of Fluorouracil Bolus (5-FU)
- Interventions
- First Posted Date
- 2018-04-23
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT03505320
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸UCLA Medical Center, Santa Monica, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or CancerMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 565
- Registration Number
- NCT03504397
- Locations
- 🇺🇸
University of Arizona, Phoenix, Arizona, United States
🇺🇸The University of Arizona Medical Center, Tucson, Arizona, United States
🇺🇸CBCC Global Research, Inc. at Comprehensive Blood and Cancer, Bakersfield, California, United States
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
- Conditions
- Bladder CancerUreteral CancerUrothelial Cancer
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 608
- Registration Number
- NCT03474107
- Locations
- 🇺🇸
UCI Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of California, Sacramento, California, United States
🇺🇸Innovative Clinical Research, Whittier, California, United States
Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03421002
- Locations
- 🇮🇹
Site IT39001, Rome, Italy
🇮🇹Site IT39002, Rome, Italy